A 25-year-old female patient presented with symptoms of extensive brown rashes all over the body with fever This case report describes a rare incidence of etoricoxib-induced toxic epidermal necrolysis (TEN) in a 25-year-old woman. The patient presented with rapidly evolving rashes, initially over the face and upper body but subsequently involving the total body surface area. There was an extensive ulceration of buccal mucosa along with eyelid edema, crusting, and corneal ulceration. Naranjo's and WHO-UMC score for this adverse event was "seven;" hence, causality was "probable." SCORTEN (severity-of-illness score) was "one" with a predicted mortality of 3.2%. Due to persistent hypotension and risk of impending sepsis, aggressive fluid resuscitation and antibiotics were initiated. Cyclosporine and systemic steroids were added later, following which the patient had a prompt recovery. She was discharged after 28 days of hospitalization. However, etoricoxib-induced TEN is a rare clinical association, with very few previously reported cases.
INTRODUCTION
Toxic epidermal necrolysis (TEN) is a severe adverse skin reaction characterized by generalized keratinocyte necrosis in relation with inappropriate immune activation by certain drugs or their metabolites. [1] It may be associated with immunosuppressive states such as HIV/AIDS, connective tissue disorders, and certain malignancies such as leukemia, lymphoma, and solid tumors. [1] Analysis of several case reports and retrospective studies have identified drugs (nearly 100) implicated in the development of Steven-Johnson Syndrome (SJS)/TEN. Etoricoxib has a 30-fold selective cyclooxygenase-2 (COX-2) enzyme inhibitor that plays a major role in the inhibition of prostaglandin synthesis. Such kind of drugs have been developed in relation with their enhanced gastrointestinal tolerability in addition with effective pain management, although postmarketing surveillance data on etoricoxib have identified cases of SJS/TEN and other skin reactions in the past. [2] In this case report, we discuss a rare incidence of etoricoxib-induced TEN in a 25-year-old woman. and peeling of skin at the emergency unit. Her past medical history included few nonspecific symptoms of polyarthralgia involving bilateral upper limb small joints. Associated history of morning stiffness, previous rashes, or photosensitivity reaction was not recorded. However, for achieving pain relief, the patient admitted taking a "better" drug, obtained from a local pharmacy over the counter. It was later confirmed by the medication label that the drug was tablet etoricoxib (60 mg), taken once daily orally with no other concurrent medication.
Subsequently, on Day 13 of continuous such medication intake, she developed a high-grade fever (>38.3°C) with chill and rigor. Her condition quickly worsened with an exaggerated skin reaction consisting of maculopapular rashes, which necessitated hospitalization. The drug was withdrawn as her condition was serious with hypotension.
The rashes had first appeared over lower limbs, followed by an eventual spread all over the entire body surface area [ Figure 1 ]. Scattered vesicles and bulla appeared subsequently, some of which got "peeled off " quickly [ Figure 2 ]. There was extensive involvement of buccal mucosa, lips, and erosion of the palate associated with eyelid edema, crusting, and discharge with corneal erosion [ Figure 3 ]. Nikolsky's sign was clearly elucidated with a detachment of the epidermis from lower layers when rubbed gently. The diagnosis of Staphylococcal Scalded Skin Syndrome (SSSS) was ruled out, attributed to the presence of mucosal involvement, which will be absent in SSSS. [3] Primary treatment included replacement of fluid loss (intravenous Ringer's lactate 500 ml 8 hourly) and maintenance of electrolyte balance and antibiotic therapy (injection clindamycin 600 mg i.v. bid + injection meropenem 1 g i.v. tid). Tablet cyclosporine (100 mg p.o. bid) was added. For local application, lignocaine 2% gel, topical liquid paraffin 15%, and moxifloxacin 0.5% w/v (ophthalmic) were prescribed.
On Day 14, laboratory investigations were mostly normal: sodium -138.7 meq/L, potassium -4.4 meq/L, creatinine -0.6 mg/dL, leukocyte count -5800/mm 3 , and platelet -2.2 lakh/μl. Hemoglobin was 8.9 g/dL. Urine culture-sensitivity analysis revealed "no obvious growth" of any microorganism. Her vitals gradually improved; hence, the treatment was continued.
On Day 20, there was a decline in hemoglobin levels to 7.9 g/dL (by 12%), for which she was transfused with 2 units of whole blood (one bag, each on Days 20 and 21, respectively). Major causes of bleeding or hemorrhage were ruled out. On Day 22, dermatological 
DISCUSSION
The underlying pathophysiology of drug-induced SJS/TEN includes predominantly CD8+ T-lymphocyte and activated macrophages in the epidermis along with CD4+ T-cells in the dermis, indicating a cytotoxic cellular immune reaction at the level of keratinocyte. They are more commonly reported in women than in men. [2, 4] Causative drugs or their metabolite act as a hapten and render keratinocyte antigenic. Underlying defect in detoxification system of keratinocyte can also play a major role in drug-induced SJS/TEN. [4, 5] Although etoricoxib is a highly selective COX-2 inhibitor, usually considered "safe" in day-to-day clinical practice, its safety attributed to an anti-inflammatory agent is still a matter of debate. [4, 6] Usually, a history of either hypersensitivity and or immunosuppression or genetic susceptibility is positive with such severe mucocutaneous reaction with this drug. [2, 4] However, the chances of developing such serious unexpected reaction with etoricoxib are still very rare. [4, 6] In most of the previous cases reported, the time period between suspected drug intake and appearance of skin lesions varied from a few days to 2-3 weeks and even 1 month in few exceptional cases. [4, 5] In the present case, a prodromal phase, characterized by fever and arthralgia, appearing after nearly 2 weeks of continuous drug intake was present. It was quickly followed by the appearance of maculopapular rash systemically, along with the formation of vesicles and bulla, with sloughing of necrotic skin extending to the extremities, back, trunk, and face. There was evidence of oral and nasal mucosal erosions with conjunctival scarring.
In the present case, the causality is "probable" to the drug etoricoxib with a score of 7, on Naranjo Adverse Drug Reaction Probability Scale [7] and WHO-UMC [8] Scale, respectively. Based on an assessment of vitals and laboratory test on admission (Day 13), SCORTEN (severity-of-illness score) was "one" with a predicted mortality of 3.2%. [9] The transient fall in the hemoglobin levels may be in parallel with some previous reports of anemia in relation with TEN. [10] However, there is no definitive explanation to whether there is any underlying bone marrow pathology specific to TEN or related to any secondary phenomenon. [10] Treatment with antibiotics (linezolid + clindamycin) along with a steroid supplement (betamethasone) was found to be effective in this case. Cyclosporine was added because of its interaction with tumor necrosis factor-α metabolism promoting shorter reepithelialization time, and the property of lowering mortality has been established previously. [1, 2] Certain drugs such as sulfonamides, nonsteroidal anti-inflammatory drugs, pyrazolones, barbiturates, and antiepileptics have been associated with triggers of TEN/SJS. [11, 12] However, chances of developing such a rare and idiosyncratic reaction with such drugs are very rare although it mandates a detailed clinical history, including drugs.
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